- Title: Subtitle
- The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
- Creators
- Ghayas C. Issa - The University of Texas MD Anderson Cancer CenterIbrahim Aldoss - City Of Hope National Medical CenterJohn F. DiPersio - Washington University in St. LouisBranko Cuglievan - The University of Texas MD Anderson Cancer CenterRichard M. Stone - Dana-Farber Cancer InstituteMartha L. Arellano - Emory UniversityMichael J. Thirman - University of ChicagoManish R. Patel - Sarah Cannon Research InstituteDavid Dickens - University of IowaShalini Shenoy - Washington University in St. LouisNeerav Shukla - Memorial Sloan Kettering Cancer CenterGalit Rosen - 12Syndax Pharmaceuticals, Inc., Waltham, MARebecca G. Bagley - 12Syndax Pharmaceuticals, Inc., Waltham, MAMichael L. Meyers - 12Syndax Pharmaceuticals, Inc., Waltham, MAKate Madigan - 12Syndax Pharmaceuticals, Inc., Waltham, MAPeter Ordentlich - 12Syndax Pharmaceuticals, Inc., Waltham, MAYu Gu - 12Syndax Pharmaceuticals, Inc., Waltham, MASteven Smith - 12Syndax Pharmaceuticals, Inc., Waltham, MAGerard M. McGeehan - 12Syndax Pharmaceuticals, Inc., Waltham, MAEytan Stein - Memorial Sloan Kettering Cancer Center
- Resource Type
- Abstract
- Publication Details
- Blood, Vol.140(Supplement 1), pp.150-152
- DOI
- 10.1182/blood-2022-164849
- ISSN
- 0006-4971
- eISSN
- 1528-0020
- Language
- English
- Date published
- 11/15/2022
- Academic Unit
- Stead Family Department of Pediatrics; Hematology/Oncology
- Record Identifier
- 9984354402902771
Abstract
The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A -Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 Study
Blood, Vol.140(Supplement 1), pp.150-152
11/15/2022
DOI: 10.1182/blood-2022-164849
Details
Metrics
53 Record Views